Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer

doi:10.12998/wjcc.v10.i15.4737

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 15

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5898)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-12) series.

Item

Count

PDF

378

WORD

HTML

2661

Figures (1-12)

673

Sum=3798

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

485

Download

1621

Sum=2106

May 26, 2022 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Clinical and Translational Research

World J Clin Cases. May 26, 2022; 10(15): 4737-4760
Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4737

Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer

Jia-Yue Zou, Yu-Jie Huang, Jun He, Zu-Xiong Tang, Lei Qin

Jia-Yue Zou, Yu-Jie Huang, Jun He, Zu-Xiong Tang, Lei Qin, Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China

Author contributions: Zou JY was responsible for data curation, methodology, and writing the original draft; Huang YJ was responsible for visualization and software; He J and Tang ZX were responsible for data collection and data curation; Qin L was responsible for writing, reviewing, and editing.

Supported by the Project of National Natural Science Foundation of China, No. 81802365 and 81802385; the Special Project of Clinical Key Diseases Treatment Technology in Suzhou, No. LCZX2019003; the City-Level Scientific Research Projects in Jiangsu Province, No. SLT201907; Major Projects of Provincial Universities in Jiangsu Province, No. 19KJA170002; Soochow University Horizontal Research Project, No. H190168.

Conflict-of-interest statement: Authors certify that there is no conflict of interest related to the manuscript.

Data sharing statement: No additional data are available.

Corresponding author: Lei Qin, MD, Doctor, Professor, Department of General Surgery, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215006, Jiangsu Province, China. qinleihbps@163.com

Received: September 13, 2021
Peer-review started: September 13, 2021
First decision: January 23, 2022
Revised: February 2, 2022
Accepted: April 2, 2022
Article in press: April 2, 2022
Published online: May 26, 2022
Processing time: 253 Days and 0.9 Hours

ARTICLE HIGHLIGHTS

Research background

Metabolic reprogramming is a feature of tumour cells and is essential to support their rapid proliferation. Lipid metabolism reprogramming enables tumour cells to meet their needs for highly proliferative growth and is an important driving force for the development of hepatocellular carcinoma (HCC).

Research motivation

We explored the influence of different metabolic subtypes of HCC and analysed their significance in guiding prognosis and treatment based on the molecular mechanism of glycolysis and fatty acid oxidation (FAO).

Research objectives

To explore the influence of different metabolic subtypes of HCC and analyse their significance in guiding prognosis and treatment.

Research methods

We utilised unsupervised consensus clustering to divide the Cancer Genome Atlas-liver hepatocellular carcinoma samples into four metabolic subgroups and compared single nucleotide polymorphism, copy number variation, tumour microenvironment, and Genomics of Drug Sensitivity in Cancer and Tumour Immune Dysfunction and Exclusion between different metabolites. In addition, we established a prognostic model based on glycolysis and FAO genes.

Research results

We established a prognostic model and found that the fatty acid oxidation group and the low-risk group had better efficacy and response to immune checkpoint blockade treatment and anti-tumour drugs.

Research conclusions

There are obvious differences in genes, chromosomes, and clinical characteristics between metabolic subgroups.

Research perspectives

The establishment of a prognostic model could predict patient prognosis and guide clinical treatment.